Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Julphar
Harvard Business School
Johnson and Johnson
QuintilesIMS
Colorcon
Express Scripts
Mallinckrodt
Fish and Richardson

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,573,293

« Back to Dashboard

Which drugs does patent 6,573,293 protect, and when does it expire?

Patent 6,573,293 protects SUTENT and is included in one NDA.

This patent has fifty-five patent family members in thirty-nine countries.
Summary for Patent: 6,573,293
Title: Pyrrole substituted 2-indolinone protein kinase inhibitors
Abstract:The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
Inventor(s): Tang; Peng Cho (Moraga, CA), Miller; Todd A. (Bend, OR), Li; Xiaoyuan (Los Altos, CA), Sun; Li (Foster City, CA), Wei; Chung Chen (Foster City, CA), Shirazian; Shahrzad (Corte Madera, CA), Liang; Congxin (Sunnyvale, CA), Vojkovsky; Tomas (San Francisco, CA), Nematalla; Asaad S. (Concord, CA), Hawley; Michael (Kalamazoo, MI)
Assignee: Sugen, Inc. (South San Francisco, CA) Pharmacia & Upjohn Co. (Kalamazoo, MI)
Application Number:09/783,264
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,573,293
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,573,293

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-001 Jan 26, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB ➤ Sign Up
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-001 Jan 26, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY ➤ Sign Up
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-002 Jan 26, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB ➤ Sign Up
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-002 Jan 26, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,573,293

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,125,905 Pyrrole substituted 2-indolinone protein kinase inhibitors ➤ Sign Up
7,572,924 Pyrrole substituted 2-indolinone protein kinase inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald
Federal Trade Commission
Teva
UBS
Baxter
Daiichi Sankyo
Chubb
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.